Verastem/$VSTM
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Verastem
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Ticker
$VSTM
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
78
Website
Verastem Metrics
BasicAdvanced
$339M
-
-$3.50
0.85
-
Price and volume
Market cap
$339M
Beta
0.85
52-week high
$9.10
52-week low
$2.10
Average daily volume
2.7M
Financial strength
Current ratio
3.501
Quick ratio
3.306
Long term debt to equity
-227.441
Total debt to equity
-236.78
Interest coverage (TTM)
-36.17%
Profitability
EBITDA (TTM)
-131.041
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,488.77%
Operating margin (TTM)
-1,310.71%
Effective tax rate (TTM)
-0.12%
Revenue per employee (TTM)
$130,000
Management effectiveness
Return on assets (TTM)
-64.19%
Return on equity (TTM)
-2,159.52%
Valuation
Price to revenue (TTM)
26.337
Price to book
-9.8
Price to tangible book (TTM)
-9.8
Price to free cash flow (TTM)
-2.287
Free cash flow yield (TTM)
-43.72%
Free cash flow per share (TTM)
-2.706
Growth
Earnings per share change (TTM)
-18.49%
3-year revenue growth (CAGR)
40.02%
3-year earnings per share growth (CAGR)
-10.79%
10-year earnings per share growth (CAGR)
-17.51%
What the Analysts think about Verastem
Analyst ratings (Buy, Hold, Sell) for Verastem stock.
Bulls say / Bears say
The FDA’s May 8, 2025 approval of Avmapki FAKZYNJA is the first treatment specifically for KRAS-mutant recurrent low-grade serous ovarian cancer, marking Verastem’s transition to a commercial-stage oncology company (Reuters)
Verastem ended Q1 2025 with $117.6 million in cash and equivalents, and a pro-forma balance of $192.6 million after its April equity raise, providing runway into late 2026 to support commercialization and R&D (SEC)
VS-7375, Verastem’s oral KRAS G12D dual ON/OFF inhibitor, received FDA Fast Track designation on July 24, 2025, and has already cleared a U.S. IND and dosed its first patient in June 2025, de-risking its lead pipeline program (Business Wire)
Verastem’s $75 million private placement in April 2025, issuing common stock and pre-funded warrants at $7.00, will dilute existing shareholders and underscores the company’s continued need to raise capital to fund operations (Business Wire)
Since its 52-week high of $9.10 on May 27, 2025, VSTM shares have fallen over 40% to trade near $5.35, reflecting waning investor confidence amid commercialization risks (CNBC)
Avmapki FAKZYNJA targets a niche indication of KRAS-mutant recurrent low-grade serous ovarian cancer affecting only about 6,000–8,000 women in the U.S., capping its peak revenue potential even with premium pricing (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 24 Jul 2025.
Verastem Financial Performance
Revenues and expenses
Verastem Earnings Performance
Company profitability
Verastem News
AllArticlesVideos
Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
Business Wire·3 days ago
Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer
Business Wire·1 week ago
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Verastem stock?
Verastem (VSTM) has a market cap of $339M as of August 01, 2025.
What is the P/E ratio for Verastem stock?
The price to earnings (P/E) ratio for Verastem (VSTM) stock is 0 as of August 01, 2025.
Does Verastem stock pay dividends?
No, Verastem (VSTM) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Verastem dividend payment date?
Verastem (VSTM) stock does not pay dividends to its shareholders.
What is the beta indicator for Verastem?
Verastem (VSTM) has a beta rating of 0.85. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.